SOCS3 is predominantly considered a negative regulator of the IL-6 induced JAK/STAT pathway which can be constitutively active in CLL due to interaction with other cells in the tumor microenvironment, or due to treatment related complications such as cytokine release following tumor lysis. This evidence concerns the gene SOCS3 and B-cell chronic lymphocytic leukemia.